Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] surged by $0.51 during the normal trading session on while it closed the day at $17.50.
Teva- Pharmaceutical Industries Ltd. ADR stock has also loss -3.15% of its value over the past 7 days. However, TEVA stock has inclined by 4.73% in the 3 months of the year. Over the past six months meanwhile, it has gained 0.29% and lost -20.60% year-on date.
The market cap for TEVA stock reached $20.07 billion, with 1.15 billion shares outstanding and 1.15 billion shares in the current float. Compared to the average trading volume of 12.00M shares, TEVA reached a trading volume of 9484439 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Teva- Pharmaceutical Industries Ltd. ADR [TEVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $24.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Teva- Pharmaceutical Industries Ltd. ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 06, 2025. While these analysts kept the previous recommendation, Truist raised their target price to Buy. The new note on the price target was released on May 28, 2025, representing the official price target for Teva- Pharmaceutical Industries Ltd. ADR stock. Previously, the target price had yet another raise to $23, while JP Morgan analysts kept a Overweight rating on TEVA stock.
The Average True Range (ATR) for Teva- Pharmaceutical Industries Ltd. ADR is set at 0.67, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 1.21. The Price to Book ratio for the last quarter was 3.21, with the Price to Cash per share for the same quarter was set at 1.48. Price to Free Cash Flow for TEVA in the course of the last twelve months was 9.63 with Quick ratio for the last quarter at 0.74.
TEVA stock trade performance evaluation
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.15. With this latest performance, TEVA shares gained by 3.73% in over the last four-week period, additionally plugging by 0.29% over the last 6 months – not to mention a rise of 1.63% in the past year of trading.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: An insightful look at the core fundamentals
Teva- Pharmaceutical Industries Ltd. ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.74 and a Current Ratio set at 1.03.
Earnings per share (EPS) analysis for Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva- Pharmaceutical Industries Ltd. ADR go to 7.35%.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: Institutional Ownership
The top three institutional holders of TEVA stocks are: BLACKROCK INC. with ownership of 42.99 million shares, which is approximately 3.7942%. FMR LLC, holding 41.98 million shares of the stock with an approximate value of $$682.15 million in TEVA stocks shares; and FMR LLC, currently with $$590.36 million in TEVA stock with ownership which is approximately 3.2065%.
